Seeking Alpha

Aegerion Pharmaceuticals (AEGR 12.1%) is flying this morning after Capstone initiates the shares...

Aegerion Pharmaceuticals (AEGR 12.1%) is flying this morning after Capstone initiates the shares with a Buy. The coverage comes on the back of last week's initiation at Overweight by JPMorgan, and just ahead of an FDA advisory meeting scheduled for October 17 - 18 to debate the risks and benefits of AEGR's experimental drug Lomitapide NDA, for the treatment of homozygous familial hypercholesterolemia. The advisory panel recommendations often heavily influence FDA approval decisions.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs